Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vebicorvir + AB-729 + nucleoside reverse transcriptase inhibitor
- Development stage
- Preclinical
- Lead developer
- Arbutus Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This triple combination therapy is being developed for the treatment of chronic hepatitis B virus (HBV) infection. The regimen consists of three distinct agents: vebicorvir, a first-generation HBV capsid assembly inhibitor (CAI); AB-729, a GalNAc-conjugated small interfering RNA (siRNA) that targets HBV RNA to reduce viral protein production, including HBsAg; and a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), which is the standard-of-care treatment for inhibiting HBV DNA replication. By simultaneously targeting multiple stages of the HBV lifecycle—capsid assembly, viral antigen production, and reverse transcription—the combination aims to achieve a functional cure for chronic HBV. Grand Theravac Life Science Nanjing is the primary developer of this specific combination regimen.
- Other names
- Vebicorvir + AB-729 + NRTI
02
Targets
HBc (Hepatitis B virus core protein)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on vebicorvir + AB-729 + nucleoside reverse transcriptase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vebicorvir + AB-729 + nucleoside reverse transcriptase inhibitor.